Novartis AG (NVS)
140.76
-0.18
(-0.12%)
USD |
NYSE |
Oct 06, 16:00
141.58
+0.82
(+0.59%)
After-Hours: 20:00
Novartis Enterprise Value : 299.71B for Oct. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 05, 2026 | 299.71B |
| October 02, 2026 | 299.84B |
| October 01, 2026 | 299.93B |
| September 30, 2026 | 302.71B |
| September 29, 2026 | 308.46B |
| September 28, 2026 | 310.60B |
| September 25, 2026 | 308.00B |
| September 24, 2026 | 304.54B |
| September 23, 2026 | 302.97B |
| September 22, 2026 | 300.35B |
| September 21, 2026 | 299.80B |
| September 18, 2026 | 298.68B |
| September 17, 2026 | 299.69B |
| September 16, 2026 | 295.63B |
| September 15, 2026 | 295.48B |
| September 14, 2026 | 296.16B |
| September 11, 2026 | 292.81B |
| September 10, 2026 | 293.39B |
| September 09, 2026 | 293.39B |
| September 08, 2026 | 293.79B |
| September 04, 2026 | 334.60B |
| September 03, 2026 | 340.27B |
| September 02, 2026 | 339.12B |
| September 01, 2026 | 336.90B |
| August 31, 2026 | 320.08B |
| Date | Value |
|---|---|
| August 28, 2026 | 323.28B |
| August 27, 2026 | 324.82B |
| August 26, 2026 | 330.11B |
| August 25, 2026 | 334.58B |
| August 24, 2026 | 330.99B |
| August 21, 2026 | 332.53B |
| August 20, 2026 | 327.73B |
| August 19, 2026 | 335.18B |
| August 18, 2026 | 324.64B |
| August 17, 2026 | 319.92B |
| August 14, 2026 | 317.92B |
| August 13, 2026 | 319.46B |
| August 12, 2026 | 320.56B |
| August 11, 2026 | 324.75B |
| August 10, 2026 | 328.74B |
| August 07, 2026 | 327.90B |
| August 06, 2026 | 324.02B |
| August 05, 2026 | 324.44B |
| August 04, 2026 | 322.30B |
| August 03, 2026 | 323.03B |
| July 31, 2026 | 327.57B |
| July 30, 2026 | 331.76B |
| July 29, 2026 | 332.47B |
| July 28, 2026 | 334.34B |
| July 27, 2026 | 327.50B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Roche Holding AG | -- |
| AstraZeneca PLC | 511.80B |
| GSK Plc | 113.62B |
| Johnson & Johnson | 637.39B |
| Eli Lilly & Co. | 1.122T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.259B |
| Revenue (Quarterly) | 14.42B |
| Total Expenses (Quarterly) | 11.15B |
| EPS Diluted (Quarterly) | 1.706 |
| Gross Profit Margin (Quarterly) | 74.47% |
| Profit Margin (Quarterly) | 22.61% |
| Earnings Yield | 4.71% |
| Operating Earnings Yield | 5.98% |
| Normalized Earnings Yield | 5.055 |